Diagnosing Alzheimer’s involves a combination of cognitive tests, brain imaging, blood work, and increasingly, biomarker tests that can detect the disease’s signature proteins. There is no single test that confirms Alzheimer’s on its own. Instead, doctors build a case by layering multiple types of evidence, ruling out other causes of memory loss, and sometimes repeating assessments over several months.
It Starts With Cognitive Testing
The first step is usually a structured test of your thinking and memory. Two of the most common are the Mini-Mental State Exam (MMSE) and the Montreal Cognitive Assessment (MoCA). Both take roughly 10 to 15 minutes and cover orientation (knowing the date, where you are), short-term recall, attention, language, and the ability to follow multi-step instructions. On the MMSE, scores below about 27 out of 30 raise concern for mild cognitive impairment, while scores below 24 point toward dementia. On the MoCA, the thresholds run a bit lower: below 24 for mild impairment, below 19 for dementia. These cutoffs shift depending on age and education level, so your doctor interprets the number in context rather than treating it as a hard line.
Doctors also want to hear from someone who knows you well. A spouse, adult child, or close friend can provide information you may not recognize in yourself. One widely used tool for this is the AD8, an eight-question screening form that asks whether a person’s thinking, judgment, or daily functioning has changed over the past few years. A score of 2 or higher (out of 8) suggests cognitive impairment is likely present. This informant interview catches early changes with over 84 percent sensitivity, meaning it picks up most cases, and over 80 percent specificity, meaning it rarely flags someone who’s cognitively healthy.
The Neurological Exam
A neurological exam isn’t looking for Alzheimer’s directly. It’s looking for signs of other brain conditions that mimic it: stroke, Parkinson’s disease, brain tumors, or a buildup of fluid in the brain. The doctor tests your reflexes, coordination, muscle tone and strength, eye movement, speech, and sensation. These checks help narrow down whether memory and thinking problems stem from Alzheimer’s or from something with a very different treatment path.
Ruling Out Other Causes
Before landing on an Alzheimer’s diagnosis, doctors need to eliminate conditions that cause similar symptoms but are treatable. Blood tests check for thyroid disorders and low levels of certain vitamins (particularly B12), both of which can impair memory and concentration. Depression, sleep disorders, and medication side effects can also look a lot like early dementia, so your doctor will ask about mood, sleep habits, and current prescriptions.
Brain imaging plays a role here too. An MRI or CT scan of the brain can reveal strokes, tumors, head injuries, or excess fluid that might explain your symptoms. These scans don’t diagnose Alzheimer’s on their own, but they’re essential for crossing other possibilities off the list.
Biomarker Tests: Detecting the Disease Itself
Alzheimer’s is defined by two abnormal proteins that accumulate in the brain: amyloid plaques (clumps of a protein fragment called amyloid-beta that build up between nerve cells) and tau tangles (twisted fibers of tau protein that form inside nerve cells). Biomarker tests look for direct evidence of these proteins, moving the diagnosis from “probable” to much more certain.
PET Scans
Specialized PET scans can visualize amyloid plaques and tau tangles in a living brain. A negative amyloid PET scan is particularly useful because it makes Alzheimer’s much less likely as the cause of symptoms, prompting doctors to investigate other possibilities like frontotemporal dementia, a mood disorder, or a sleep condition. A positive scan increases the likelihood that Alzheimer’s is the primary driver. Tau PET scans add another layer: the tracers used bind strongly to Alzheimer’s-type tau tangles but show little to no binding in other brain diseases that involve tau, making them helpful for distinguishing Alzheimer’s from conditions like progressive supranuclear palsy or chronic traumatic encephalopathy.
Spinal Fluid Analysis
A lumbar puncture (spinal tap) collects cerebrospinal fluid, which bathes the brain and spinal cord. In Alzheimer’s, the ratio of two forms of amyloid-beta in this fluid drops. Mayo Clinic Laboratories considers a ratio of 0.073 or above normal, while 0.058 or below is consistent with a positive amyloid PET scan, meaning significant plaque buildup is present. Values between 0.059 and 0.072 fall into a gray zone that’s more likely abnormal than not.
Blood Tests for Alzheimer’s Proteins
The newest and most accessible biomarker option is a blood test measuring a specific form of tau protein called p-tau217. As a standalone test, it identifies Alzheimer’s pathology with about 81 percent accuracy. When doctors confirm an abnormal blood result with a follow-up PET scan, accuracy climbs to 91 percent. A large study published in JAMA Neurology found the p-tau217 blood test performed as well as a spinal fluid test and reduced the need for confirmatory PET scans by roughly 80 percent. This is a significant shift: what once required a spinal tap or an expensive PET scan can now begin with a simple blood draw, making early detection far more practical.
What Genetic Testing Does (and Doesn’t) Tell You
You may have heard of the APOE-e4 gene, the strongest known genetic risk factor for late-onset Alzheimer’s. A test for this gene is available, but it doesn’t diagnose the disease. Carrying one copy of the APOE-e4 variant increases your risk; carrying two copies increases it further. But many people with the variant never develop Alzheimer’s, and many people without it do. The test is voluntary and most useful in two scenarios: if you have a strong family history and want to understand your personal risk, or if you already have Alzheimer’s and your doctor wants to guide treatment decisions, since some newer therapies work differently depending on APOE status.
How Long the Process Takes
The diagnostic workup can stretch over several appointments and many months, particularly when symptoms are mild or the picture is unclear. An initial visit with a primary care doctor often involves cognitive screening, blood work, and a referral for brain imaging. If results are ambiguous, you may be referred to a neurologist or a memory clinic, where more specialized testing, including biomarker analysis, takes place. In straightforward cases, a diagnosis can come together faster. But because Alzheimer’s is a progressive disease, doctors sometimes track changes over time, repeating cognitive tests months apart to see whether scores are declining. That pattern of worsening, combined with biomarker evidence, is what ultimately confirms the diagnosis.
The Shift Toward Biological Diagnosis
Historically, Alzheimer’s was diagnosed based on symptoms alone, and a definitive answer came only from examining brain tissue after death. That’s changed dramatically. Updated 2024 criteria from a joint workgroup define Alzheimer’s as a biological disease, not just a clinical syndrome. The disease is now understood as a continuum with three stages: a preclinical stage where brain changes are present but no symptoms exist, mild cognitive impairment due to Alzheimer’s, and dementia due to Alzheimer’s. Diagnosis at any stage rests on abnormal biomarkers, not just a doctor’s clinical impression. Blood-based biomarkers, in particular, have been formally incorporated into the updated criteria, reflecting how rapidly the field has moved toward earlier and more precise detection.